Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.
molecular imaging
nuclear medicine
therapeutics
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Oct 2021
24 Oct 2021
Historique:
received:
12
09
2021
revised:
20
10
2021
accepted:
21
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms ("prostate cancer", "prostatic neoplasms") and ("radioligand", "radiotracer"). Included articles were clinical studies. The results were synthetized by the target type. We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) ( Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.
Sections du résumé
BACKGROUND
BACKGROUND
Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans.
METHODS
METHODS
We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms ("prostate cancer", "prostatic neoplasms") and ("radioligand", "radiotracer"). Included articles were clinical studies. The results were synthetized by the target type.
RESULTS
RESULTS
We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (
CONCLUSION
CONCLUSIONS
Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.
Identifiants
pubmed: 34768432
pii: jcm10214909
doi: 10.3390/jcm10214909
pmc: PMC8584491
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Theranostics. 2014 Feb 01;4(4):412-9
pubmed: 24578724
Theranostics. 2015 Sep 13;5(12):1303-16
pubmed: 26516369
J Clin Oncol. 2021 Apr 10;39(11):1274-1305
pubmed: 33497248
Diagnostics (Basel). 2021 Jun 14;11(6):
pubmed: 34198666
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Jan - Feb;38(1):29-37
pubmed: 30442558
EJNMMI Res. 2019 Jul 30;9(1):70
pubmed: 31363939
Eur J Nucl Med Mol Imaging. 2016 May;43(5):964-973
pubmed: 26631238
Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):344-50
pubmed: 15726353
Cancer Res. 1999 Apr 1;59(7):1655-64
pubmed: 10197643
Nucl Med Commun. 2001 Jan;22(1):5-15
pubmed: 11233552
Mol Pharmacol. 1995 Jan;47(1):10-20
pubmed: 7838118
JAMA Oncol. 2018 Feb 1;4(2):217-224
pubmed: 29121144
Mol Imaging Biol. 2010 Jan-Feb;12(1):78-84
pubmed: 19421819
Nucl Med Biol. 2021 May-Jun;96-97:54-60
pubmed: 33831746
J Clin Oncol. 2017 Jun 10;35(17):1952-1964
pubmed: 28441112
J Nucl Med. 2021 Nov;62(11):1517-1523
pubmed: 33789933
Eur J Nucl Med Mol Imaging. 2021 Jul 5;:
pubmed: 34226953
J Nucl Med. 2019 Aug;60(8):1111-1117
pubmed: 30630941
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508
pubmed: 29247284
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):123-135
pubmed: 31482426
J Urol. 2013 Aug;190(2):441-9
pubmed: 23707439
J Nucl Med. 2018 Oct;59(10):1516-1523
pubmed: 29626121
Mol Imaging Biol. 2014 Dec;16(6):888-95
pubmed: 24915934
J Nucl Med. 2021 Mar;62(3):354-359
pubmed: 32764119
J Nucl Med. 2004 Nov;45(11):1966-71
pubmed: 15534070
EJNMMI Res. 2020 Jun 12;10(1):62
pubmed: 32533273
Mol Ther Oncolytics. 2020 Jun 24;18:226-235
pubmed: 32728611
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Experientia. 1971 Feb 15;27(2):166-7
pubmed: 5544731
Eur Urol Oncol. 2019 Mar;2(2):166-173
pubmed: 31017093
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Nucl Med. 2011 Nov;52(11):1727-32
pubmed: 21984797
J Nucl Med. 2018 Jun;59(6):922-928
pubmed: 29123014
J Nucl Med. 2017 Jan;58(1):75-80
pubmed: 27493272
Tumori. 2002 May-Jun;88(3):S28-30
pubmed: 12365378
Prostate. 2009 Jul 1;69(10):1101-8
pubmed: 19343734
J Nucl Med. 2021 Nov;62(11):1545-1549
pubmed: 33674398
J Nucl Med. 2021 Jun 24;:
pubmed: 34168013
J Med Radiat Sci. 2017 Mar;64(1):52-60
pubmed: 28303694
Cancer Res. 1995 Dec 1;55(23 Suppl):5805s-5810s
pubmed: 7493350
J Nucl Med. 2017 Feb;58(2):228-234
pubmed: 27493267
Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1378-82
pubmed: 12920485
Mol Med Rep. 2015 May;11(5):3203-11
pubmed: 25593080
Front Endocrinol (Lausanne). 2021 May 19;12:679000
pubmed: 34093445
J Nucl Med. 2015 Mar;56(3):372-8
pubmed: 25678494
Eur J Nucl Med. 2000 Nov;27(11):1694-9
pubmed: 11105826
Cold Spring Harb Perspect Biol. 2011 Mar 01;3(3):
pubmed: 21421922
Radiology. 2014 Apr;271(1):220-9
pubmed: 24475817
J Nucl Med. 2018 May;59(5):803-808
pubmed: 29084827
Cancer Biother Radiopharm. 2014 Apr;29(3):108-15
pubmed: 24450327
J Nucl Med. 2010 Feb;51(2):183-92
pubmed: 20080885
Clin Nucl Med. 2017 Jan;42(1):1-6
pubmed: 27775942
Clin Genitourin Cancer. 2021 Aug;19(4):e200-e205
pubmed: 33678552
J Nucl Med. 2017 Mar;58(3):379-386
pubmed: 27609788
J Nucl Med. 2016 Apr;57(4):557-62
pubmed: 26659347
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1463-1472
pubmed: 28417160
J Nucl Med. 2019 Sep;60(9):1221-1227
pubmed: 30850488
Nuklearmedizin. 2019 Sep;58(5):352-362
pubmed: 31443113
Clin Cancer Res. 2013 Oct 1;19(19):5434-43
pubmed: 23935037
J Nucl Med. 2004 Mar;45(3):366-73
pubmed: 15001675
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
EJNMMI Res. 2018 Dec 12;8(1):108
pubmed: 30543050
Oncotarget. 2016 May 10;7(19):28151-9
pubmed: 27058620
Prostate. 2012 Feb;72(3):318-25
pubmed: 21739464
J Nucl Med. 2008 Feb;49(2):318-26
pubmed: 18199616
Cancers (Basel). 2019 Nov 23;11(12):
pubmed: 31771198
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63
pubmed: 24130224
Nucl Med Biol. 2019 Mar;70:32-38
pubmed: 30836254
ACS Med Chem Lett. 2013 Mar 18;4(5):491-6
pubmed: 24900696